Financial support from the DFG, the Fonds der Chemischen Industrie, the country NRW and the EU (Europäischer Fonds für regionale Entwicklung) is gratefully acknowledged.
1521-3773/asset/2002_left.gif?v=1&s=ac6b0d94a94d7ce7a210002b8096b42feffc0bcf)
1521-3773/asset/2002_right.gif?v=1&s=451042aa3415ae3ad0729984d26dee1866aca82e)
Communication
Small-Molecule Inhibitors of Islet Amyloid Polypeptide Fibril Formation†
Article first published online: 9 MAY 2008
DOI: 10.1002/anie.200705372
Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Additional Information
How to Cite
Mishra, R., Bulic, B., Sellin, D., Jha, S., Waldmann, H. and Winter, R. (2008), Small-Molecule Inhibitors of Islet Amyloid Polypeptide Fibril Formation. Angew. Chem. Int. Ed., 47: 4679–4682. doi: 10.1002/anie.200705372
- †
Publication History
- Issue published online: 3 JUN 2008
- Article first published online: 9 MAY 2008
- Manuscript Revised: 4 JAN 2008
- Manuscript Received: 22 NOV 2007
Funded by
- DFG
- Fonds der Chemischen Industrie
- country NRW
- EU (Europäischer Fonds für regionale Entwicklung)
Keywords:
- amylin;
- amyloid;
- IAPP;
- small-molecule inhibitors;
- type-II diabetes
Small and effective: The pathological aggregation of amylin (IAPP), which leads to type II diabetes mellitus, is effectively inhibited by small-molecule rhodanine-based inhibitors at nanomolar concentrations. The prevention of aggregation by treatment with the inhibitor is demonstrated by AFM (see image).